FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer
/PRNewswire/ -- Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today...
United States Basel Stadt Katrin Rupalla Society For Immunotherapy Of Cancer Us Food Drug Administration National Library Of Medicine
Source: prnewswire.com